Form 4: Dorman Products Executive Exercises Options, Sells Shares

Sentiment:

Insider Transaction Report 3 December 2025 4:05 PM

John McKnight, President of Heavy Duty at Dorman Products, exercised stock options and subsequently sold a portion of the acquired common stock on December 1, 2025, under a Rule 10b5-1 plan.

Summary

John McKnight, President, Heavy Duty at Dorman Products, Inc. (DORM), engaged in multiple transactions involving the company's common stock and employee stock options on December 1, 2025.
McKnight acquired a total of 4,632 shares of common stock through the exercise of employee stock options at prices ranging from $73.72 to $101.45.
Concurrently, McKnight disposed of a total of 4,898 shares of common stock through sales at weighted average prices of $130.595 and $131.19.
These transactions were conducted pursuant to a Rule 10b5-1 pre-arranged trading plan.
Following these transactions, McKnight beneficially owns 11,112.1061 shares of Dorman Products common stock directly.
Remaining derivative securities include 1,392 employee stock options exercisable at $73.72, 623 options at $96.36, and 1,406 options at $91.28.

Sentiment

Score: 5

Explanation: The executive exercised stock options to acquire shares and then sold a slightly larger number of shares. While the exercise indicates value realization, the net reduction in direct holdings, even under a pre-arranged plan, can be interpreted neutrally to slightly negatively by the market.

Positives

The executive exercised stock options, indicating a realization of value from previously granted equity incentives.
The transactions were conducted under a Rule 10b5-1 plan, suggesting a pre-scheduled event rather than a reaction to immediate company performance or market conditions.

Negatives

The executive sold a significant number of shares (4,898 shares) at prices above $130, resulting in a net reduction of direct common stock holdings.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders: May view the net sale of shares by an executive as a slight negative signal, although the Rule 10b5-1 plan mitigates immediate concerns about market timing.

Key Dates

Date	Description
11/01/2020	First anniversary of grant date for options exercisable at $73.72, beginning four equal annual installments of vesting.
03/02/2022	First anniversary of grant date for options exercisable at $101.45, beginning four equal annual installments of vesting.
03/02/2023	First anniversary of grant date for options exercisable at $96.36, beginning four equal annual installments of vesting.
03/02/2024	First anniversary of grant date for options exercisable at $91.28, beginning four equal annual installments of vesting.
12/01/2025	Date of earliest transaction for both common stock acquisitions/dispositions and derivative security exercises.
12/03/2025	Signature date of the reporting person (via Power of Attorney) for the Form 4 filing.
11/01/2027	Expiration date for employee stock options exercisable at $73.72.
03/02/2029	Expiration date for employee stock options exercisable at $101.45 (all exercised).
03/02/2030	Expiration date for employee stock options exercisable at $96.36.
03/02/2031	Expiration date for employee stock options exercisable at $91.28.

Recommendation

hold

The filing details routine insider transactions (option exercises and subsequent sales) executed under a pre-arranged 10b5-1 plan. While there's a net reduction in the executive's direct shareholdings, the pre-planned nature suggests it's not a reaction to new, adverse information. Without additional company-specific or market-wide information, these transactions alone do not provide a strong signal for a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate as it reflects a neutral stance pending further data.

Keywords

Dorman Products, DORM, SEC Form 4, Insider Trading, Stock Options, Equity Sales, Executive Compensation, Rule 10b5-1, John McKnight

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.